Keratoconus Clinical Trial
Official title:
Custom Anterior Surfacing of Scleral Lens for Vision Quality Improvement in Patients With Keratoconus
The goal of the study is to examine the effects of custom front-surface wavefront correction on visual performance, and on neutralization of higher order aberrations, in patients wearing a scleral lens device. The investigators will study patients with keratoconus, the most common type of corneal ectasia, who have already been fitted with the BostonSight BSS (Boston Sight Scleral) for improved visual function.
This study will be a single center, double-masked collection of data taking place at the
Flaum Eye Institute. Informed consent will be obtained from all subjects after a thorough
explanation of the nature and possible risks of the study. Flaum Eye Institute electronic
health records of existing patients will first be screened by an optometrist or
ophthalmologist to verify that they do not fall under the exclusion criteria. Some study
communication regarding scheduling will be done over the phone or email. The screening will
be similar to a standard eye exam (without eye dilation) and will include a slit lamp
examination as well as visual acuity and basic vision evaluation.
The study eye will be chosen based on inclusion criteria; if both eyes qualify, the eye with
worse best corrected acuity will be chosen. A new lens will be manufactured for the subject
after the screening visit and will be given to the subject during the following study visit.
This is done to ensure fully neutralized spherical refractive effort and positional
stability. If screening evaluation reveals that the current lens does not fully neutralize
spherical refractive error or that the current lens is not positionally stable, a baseline
lens will be manufactured that corrects this. The subject will be allowed to keep the old
lens if he or she so chooses.
At the second visit, the patient's vision and fit will be evaluated with the optimized
baseline BSS lens. Visual acuity and device fit will be evaluated and recorded. If the BSS
device fit is still not optimized, then a new device will be made , and the second visit
evaluation will be rescheduled. Once the baseline lens design is determined to be
satisfactory, the patient will have their wavefront aberration measured with a wavefront
sensor. Investigators will dilate the pupil pharmacologically with phenylephrine (2.5%) and
tropicamide (1%) and take wavefront measurements of the optical aberrations of the subject's
eye wearing the baseline lens using a portable, non-invasive wavefront analyzer designed to
measure highly aberrated eyes (Ovitz, P10/EyeProfiler). The investigators will then design
and manufacture a study lens that is identical in design to the baseline BostonSight BSS lens
except for a custom front surface designed to neutralize the optical aberrations measured
with the wavefront analyzer. This HOA-optimized lens will be created prior to the third
visit.
At the third visit the patient's vision and fit will be evaluated with the new HOA-optimized
lens. A designated study team member will measure visual acuity and over-refraction of the
patient. If an adjustment is needed for the lens, then a new device will be made, and the
third visit evaluation will be rescheduled.
Once well-fitting baseline and HOA-optimized test lenses are established, both lenses will be
remade and presented to the evaluator designated study team member in charge of evaluation
and subject together in a masked fashion. During a fourth visit, the patient's vision will be
extensively evaluated using standard non-invasive optometric measurements with each of the
two lenses. First the patient will undergo a basic evaluation with each lens to ensure that
the fit is correct. The patient will then undergo basic visual acuity; high and low contrast
visual acuity, contrast sensitivity, and subjective vision scoring with each lens. The
subject's wavefront aberration will also be measured again with each lens.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04570020 -
Scleral Lens Fitting Using Wide-Field OCT
|
||
Recruiting |
NCT02921009 -
McNeel Eye Center Corneal Crosslinking Study
|
N/A | |
Completed |
NCT01691651 -
Botulinum Toxin A for the Treatment of Keratoconus
|
N/A | |
Terminated |
NCT02762253 -
Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking in Eyes With Keratoconus.
|
Phase 2 | |
Completed |
NCT01527708 -
Accuracy of Curvature and Wavefront Aberrations of Posterior Corneal Surface, in Keratoconic and Post-CXL Corneas
|
N/A | |
Completed |
NCT01527721 -
Blurring Strength & Aberrometric Changes Following Corneal Cross-linking (CxL) and CxL Combined With Photorefractive Keratectomy (PRK) in Keratoconus
|
N/A | |
Recruiting |
NCT00841386 -
Treatment of Keratoconus Using Collagen Cross-Linking
|
Phase 2/Phase 3 | |
Completed |
NCT00347074 -
A Clinical Study of Keratoconus in Asian Patients and Assessment of Different Topographic Patterns of Keratoconus in Asian Patients
|
N/A | |
Completed |
NCT03187912 -
Accelerated Corneal Cross-linking With Different Riboflavin Solutions
|
Phase 3 | |
Completed |
NCT00584285 -
Corneal Topographer Fluorescein Patterns
|
||
Completed |
NCT03511495 -
Reliability of Topography Measurements in Keratoconus
|
||
Not yet recruiting |
NCT05395650 -
Cyanocobalamin as Photosensitizing Agent
|
||
Completed |
NCT04418999 -
Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus
|
Early Phase 1 | |
Completed |
NCT05019768 -
Topo-pachimetric Accelerated Epi-On Cross-linking Compared to Dresden Protocol Using Riboflavin With Vitamin E TPGS
|
N/A | |
Completed |
NCT03235856 -
Retrospective Digital Computer Analysis of Keratoconus Evolution - REDCAKE
|
||
Withdrawn |
NCT01789333 -
Higher Irradiance in Keratoconus Ectasia
|
N/A | |
Completed |
NCT05114928 -
Correlation Between Q-value Changes and Progression of Pediatric Keratoconus.
|
||
Recruiting |
NCT04439552 -
fMRI and IVCM Cornea Microscopy of CXL in Keratoconus
|
||
Recruiting |
NCT06100939 -
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
|
Phase 3 | |
Completed |
NCT02444923 -
Scleral Versus Corneal RGP Contact Lenses in Irregular Cornea Disorders
|
N/A |